Want to see CL full AI Analyst Report?
Earnings Data
Report Date
Jul 31, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.95Last Year’s EPS
0.92Same Quarter Last Year
Moderate Buy
Based on 17 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call balanced encouraging operational and strategic progress — accelerated organic sales, volume + pricing gains excluding private-label pet impact, strong Hill's performance, emerging-market momentum, and an expanded productivity program — against meaningful near-term margin headwinds: roughly $300 million of incremental cost pressure, elevated commodity and logistics inflation (>20% and ~10% respectively), gross margin degradation, North America underperformance, and temporary private-label pet disruption. Management maintained overall sales and EPS guidance and emphasized offset plans (RGM, pricing via innovation, productivity/SGPP, disciplined advertising), but acknowledged persistent macro uncertainty.Company Guidance
Top- and Bottom-Line Growth
Company reported strong top- and bottom-line growth in Q1 2026 and delivered growth in gross profit, operating profit, EPS and free cash flow while increasing brand and capability investments.
Organic Sales Acceleration
Organic sales growth accelerated sequentially from Q4, with management maintaining full-year organic sales guidance of 1% to 4%.
Volume and Pricing Strength (Excluding Private Label Pet Exit)
Excluding the impact of the private-label pet food exit, the business grew both volume and pricing across all 4 categories and 4 of 5 divisions; Hill's volume (ex private label) was up 1%.
Emerging Markets Lead Performance
Sales growth was led by emerging markets, notably Asia Pacific (China & India) and Latin America (Mexico and Brazil), with Asia Pacific described as a major driver and LatAm delivering mid-single-digit growth.
Hill's Strong Performance
Hill's delivered solid organic growth ex private label of 4.8% overall (U.S. grew ~5%), with strong growth in Prescription Diet and Science Diet segments and share gains across many channels.
Strategic Productivity Program (SGPP) Expansion
Updated strategic growth & productivity program with expected savings of $200 million to $300 million over the program term (majority flowing in 2027–2028) while keeping program completion by end of 2028.
Continued Investment in Growth Capabilities
Company is increasing investment in advertising, omnichannel demand generation, innovation, data/analytics and AI; management highlighted improving ROI on increased advertising spend and prioritized innovation-led pricing opportunities.
CL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2026 | $85.36 | $87.26 | +2.23% |
Jan 30, 2026 | $84.71 | $89.73 | +5.92% |
Oct 29, 2025 | $76.20 | $74.80 | -1.83% |
Aug 01, 2025 | $82.27 | $81.94 | -0.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Colgate-palmolive Company (CL) report earnings?
Colgate-palmolive Company (CL) is schdueled to report earning on Jul 31, 2026, Before Open (Confirmed).
What is Colgate-palmolive Company (CL) earnings time?
Colgate-palmolive Company (CL) earnings time is at Jul 31, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CL EPS forecast?
CL EPS forecast for the fiscal quarter 2026 (Q2) is 0.95.
